A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design

被引：0
|
作者：
Riedl, M. [1 ]
Bernstein, J. A. [2 ]
Craig, T. [3 ]
Banerji, A. [4 ]
Magerl, M. [5 ]
Cicardi, M. [6 ,7 ]
Longhurst, H. J. [8 ]
Shennak, M. [9 ]
Yang, W. [10 ]
Schranz, J. [11 ]
Baptista, J. [11 ]
Busse, P. [12 ]
机构：
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Cincinnati, Coll Med, Dept Internal Med, Allergy Sect Cincinnati, Cincinnati, OH USA
[3] Penn State Hershey Allergy Asthma & Immunol, Dept Med & Pediat, Hershey, PA USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA USA
[5] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[6] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy
[7] Luigi Sacco Hosp Milan, Milan, Italy
[8] Barts Hlth NHS Trust, Dept Immunol, London, England
[9] Triumpharma Inc, Amman, Jordan
[10] Univ Ottawa, Med Sch, Ottawa Allergy Res Corp, Ottawa, ON, Canada
[11] Shire, Lexington, MA USA
[12] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol & Allergy, New York, NY 10029 USA
来源：
ALLERGY | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1059
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [21] Icatibant is effective in the treatment of acute attacks of hereditary angioedema: updates on the open-label extension arm of a phase III clinical trial
    Bork, K.
    [J]. ALLERGY, 2009, 64 : 281 - 282
  • [22] Consolidated results from the open-label extension study of ecallantide for the treatment of acute attacks of hereditary angioedema
    Riedl, M.
    MacGinnitie, A.
    Stolz, L.
    [J]. ALLERGY, 2011, 66 : 109 - 109
  • [23] Ongoing open-label extension study of ecallantide for the treatment of acute attacks of hereditary angioedema: interim results
    MacGinnitie, A.
    Pullman, W.
    Patrick, H.
    [J]. ALLERGY, 2010, 65 : 13 - 14
  • [24] Efficacy and safety of Cinryze for the prevention of hereditary angioedema attacks in children: interim results of a Phase 3 study
    Aygoren-Pursun, E.
    Moldovan, D.
    Christensen, J.
    van, Leerberghe A.
    Wu, Y.
    Schranz, J.
    Martinez-Saguer, I
    Soteres, D.
    [J]. ALLERGY, 2016, 71 : 296 - 296
  • [25] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study
    Paes, Kim
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Ren, Hong
    Craig, Timothy
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB145 - AB145
  • [26] Icatibant for the treatment of laryngeal attacks in hereditary angioedema: an update of the FAST-3 study and its open-label extension
    Moldovan, D.
    Toubi, E.
    Li, H.
    Reidl, M.
    [J]. ALLERGY, 2013, 68 : 120 - 120
  • [27] Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks A Randomized Clinical Trial
    Banerji, Aleena
    Riedl, Marc A.
    Bernstein, Jonathan A.
    Cicardi, Marco
    Longhurst, Hilary J.
    Zuraw, Bruce L.
    Busse, Paula J.
    Anderson, John
    Magerl, Markus
    Martinez-Saguer, Inmaculada
    Davis-Lorton, Mark
    Zanichelli, Andrea
    Li, H. Henry
    Craig, Timothy
    Jacobs, Joshua
    Johnston, Douglas T.
    Shapiro, Ralph
    Yang, William H.
    Lumry, William R.
    Manning, Michael E.
    Schwartz, Lawrence B.
    Shennak, Mustafa
    Soteres, Daniel
    Zaragoza-Urdaz, Rafael H.
    Gierer, Selina
    Smith, Andrew M.
    Tachdjian, Raffi
    JamesWedner, H.
    Hebert, Jacques
    Rehman, Syed M.
    Staubach, Petra
    Schranz, Jennifer
    Baptista, Jovanna
    Nothaft, Wolfram
    Maurer, Marcus
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (20): : 2108 - 2121
  • [28] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Long-Term Prophylaxis Use: Interim Results From the HELP Open-Label Extension Study
    Paes, Kim
    Craig, Timothy
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Nurse, Christina
    Zuraw, Bruce
    Jacobs, Joshua
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB102 - AB102
  • [29] Garadacimab for hereditary angioedema prophylaxis in adolescents: efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)
    Magerl, M.
    Saguer, I. Martinez
    Jacos, J. S.
    Li, H.
    Bernstein, J. A.
    Hsu, C.
    Sitz, K. V.
    Pragst, I.
    Feuersenger, H.
    Wieman, L.
    Pollen, M.
    Rese, A.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 562 - 562
  • [30] TWO-YEAR ANALYSIS OF THE DONIDALORSEN PHASE 2 OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Cohn, D.
    Newman, K.
    Bordone, L.
    Deng, Y.
    Alexander, V.
    Dorow, S.
    Riedl, M.
    Schneider, E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S28 - S28
12345